Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Indian Stent Maker...

    Indian Stent Maker Translumina sells stake to PE Everstone for Rs 500 crore: Report

    Farhat NasimWritten by Farhat Nasim Published On 2019-08-27T15:31:18+05:30  |  Updated On 13 Aug 2021 4:39 PM IST

    Mumbai: Cardiac stents and cardiovascular medical devices maker, Translumina Therapeutics is reported to have sold its minority stake to Private Equity firm Everstone in a deal worth Rs 500 crore.


    As per a recent media report by Economic Times, the funds raised in this deal will be utilised by Translumina in expanding the company's footprints on a global platform. The amount will be invested in buying global assets, augmenting its RnD efforts. Besides, the Indian manufacturing capabilities and enhancement of the company's distribution ecosystem will also be worked upon using the fund.


    The Indian Stent market, one of the largest in the world, underwent a major change in the year 2017 when the government announced a blanket price cap on cardiac stents according to their category. The price cap immediately hit the MNCs forcing many to withdraw their stents from the Indian Market. The move turned to be a golden opportunity for Indian Stent makers and domestic manufacturers have now increased their shares in the market which now stands at 60%.

    Read also: Abbott decides to withdraw 2 stent types from India

    Translumina, which currently ranks among the top three domestic stent makers owns around 15 per cent share of the Rs 1,500 crore stents market in India. The company had created its first drug-eluting stent from India for the world in partnership with the German Heart Centre in Munich in 2011.


    Prior to this, while expressing about the company's planning to fund its future expansion, Chairman, Translumina, Gurmit Singh Chugh had stated "To scale up our international presence we need investments for which we are looking for a large private equity investor. Till now all our growth has been through internal accruals."


    Also Read: Translumina eyes 25 per cent of stents market by 2018-end

    Arjun Oberoi, managing director at Everstone Group told ET, "Translumina is extremely well-positioned to emerge as a global leader in stents and cardiovascular technologies at highly affordable prices. Everstone's expertise in healthcare will help unlock the company's full potential by scaling manufacturing, strengthening its global distribution and driving new product development."

    The company distribute its products in more than 30 countries across the globe.

    Arjun Oberoicardiac stentCardiovascular Devicesdomestic stent makerEverstonegovt of indiaMedical DevicesPE firmprice capPrivate equityStentStent market indiaStent pricestent price capstentmakerTranslumina
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok